Bolder BioPath Bolder BioPATH, Inc.

  • About Us
  • Services
    • In Vivo efficacy models
    • In Vitro Services
    • Ex Vivo Services
    • Pathology
    • Model Development
  • Publications
  • Request a Quote
  • Contact

Tell Us About Your Project! Get a Quote »

Contact Us

  • This field is for validation purposes and should be left unchanged.

Recent Posts

  • Inotiv, Inc. Announces Expansion of Pharmacology and Pathology Offerings with Agreement to Purchase Bolder BioPATH, Inc.

    04-16-21

    WEST LAFAYETTE, Ind., April 16, 2021 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of non-clinical and analytical contract research services, today announced that the Company has entered into an agreement and plan of merger with Bolder BioPATH, Inc. (“Bolder BioPATH”), a contract pharmacology and pathology company specializing […]

    We are eager to help you continue your drug development & discovery programs

    03-27-20

    In these trying time, we know the importance of having suppliers that you can count on.  We have implemented advanced cleaning schedules, flexible work hours and enhanced employee screening, to ensure that our operations can continue uninterrupted.  Please reach out to us if we can be of service.

  • Covid-19 Response as Operations Continue

    03-20-20

    Bolder BioPATH takes pride in our ability to provide great quality and value in the contract research services space while maintaining our customer’s timelines.  In the midst of the current uncertain environment, the entire Bolder BioPATH team is fully engaged and taking decisive action to ensure our customers’ study timelines stay on track while doing our part to keep […]

    Please come join us at the Keystone Symposia on Tissue Immunity (Jan 26-29, 2020 in Boulder, CO)

    12-02-19

    Summary of  meeting: How tissues integrate host-microbial signals and regulate immune responses has a critical impact on health and disease. However, our understanding of tissue immunity is limited because of difficulties in accessing the different organs and also due to the inherent complexity and individuality of the cellular circuits present in different tissues. This conference […]

  • Exciting Changes Coming in 2020!

    10-08-19

    BBP is expanding into an additional 16,000 sf, with updated wet labs and a second vivarium. New disease areas and models coming in 2020!

    A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

    05-02-17

    Come hear Leo Fitzpatrick discuss the paper, A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice, this Saturday May 6, from 10:30am-10:45am in Room S102d at McCormick Place, California NorthState University College of Pharmacy. Authors: Leo Fitzpatrick, Robert O’Connell, George Talbott, Phillip Bendele, Gordon Alton, Jim Zapf

  • AAALAC Accreditation

    03-14-17

    Bolder BioPATH now has FULL accreditation through AAALAC International, effective as of March 9, 2017.

    OARSI 2017 World Congress on Osteoarthritis

    01-24-17

    Come meet Bolder BioPATH at the OARSI 2017 World Congress on Osteoarthritis in Las Vegas from April 27 to 30! We’ll be set up in booth #8.

Website designed by Studio98

  • In Vivo efficacy models
  • In Vitro Services
  • Ex Vivo Services
  • Pathology
  • Terms of Service
  • Privacy Policy

©2020 Bolder BioPATH, INC. All rights reserved.Privacy Policy